Anlotinib as Third-Line or Later Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Real-World Efficacy and Safety Outcomes.

Consistently, tumors with PI3K pathway activation (defined as PIK3CA mutation or PTEN loss) did not demonstrate a survival advantage ( Figure 4B ). In univariable Cox regression analyses of individual gene alterations ( Figure 4B ), alterations in PIK3CA, PTEN, MTOR, and several related genes were not associated with improved PFS, and in some cases showed a trend toward shorter survival.

also in 53,322 other papers